Scalper1 News
Medical diagnostic systems and research services providers got a shot in the arm Wednesday as Myriad Genetics (MYGN) gapped up to its highest level in nearly five years. Myriad (98 Composite Rating) surged 4.03, or 11%, to 39.18 in huge volume. The IBD 50 stock is 15% past a 34 buy point of a cup with handle it cleared Feb. 18. The Salt Lake City-based company updated its pricing for its BRAC-Analysis tests, which are used to gauge a woman’s risk Scalper1 News
Scalper1 News